More oncology practices plan drug cost-benefit analyses

10/30/2013 | Pharmalot

The proportion of oncologists with the data capability to analyze drug costs and outcomes is expected to rise from 11% now to 40% two years from now, according to a survey by Reimbursement Intelligence and the Cancer Business Center Summit. Half of the oncologists, hospital directors and data administrators surveyed said they track adverse events, 67% said the cost of chemotherapy drugs is the most important data point to track and 65% said overall drug cost is most important.

View Full Article in:

Pharmalot

Published in Briefs: